HLA-B*5701 screening for hypersensitivity to abacavir by Mallal Simon, Phillips Elizabeth, Carosi Giampiero, Molina Jean-Michel, Workman Cassy, Tomazic Janez, J├Ągel-Guedes Eva, Rugina Sorin, Kozyrev Oleg, Cid Juan Flores, Hay Phillip, Nolan David, Hughes Sara, Hughes Arlene, Ryan Susanna, Fitch Nicholas, Thorborn Daren, Benbow Alastair, PREDICT-1 Study Team in The New England journal of medicine (2008).

[PMID: 18256392] PubMed

Abstract

Hypersensitivity reaction to abacavir is strongly associated with the presence of the HLA-B*5701 allele. This study was designed to establish the effectiveness of prospective HLA-B*5701 screening to prevent the hypersensitivity reaction to abacavir.

[ hide abstract ]

Discussed In Paper

Loading...

Variant Annotations

Sign in to see variant annotations.

Dosing Information

Dosing Annotation for abacavir and HLA-B

Main Findings

Prospective screening for HLA-B*57:01 eliminated immunologically confirmed abacavir hypersensitivity reactions (p<0.001) and reduced clinically diagnosed hypersensitivity reactions (p<0.001)

Dosing Protocol

Prospective screening (n=803)Standard-of-care (n=847)
HLA-B*57:01 patients excluded from abacavir treatmentNo screening for HLA-B*57:01
3.4% developed clinically diagnosed hypersensitivity7.8% developed clinically diagnosed hypersensitivity
0% developed immunologically-confirmed abacavir hypersensitivity2.7% developed immunologically-confirmed abacavir hypersensitivity

Additional Information

  • Ethnicity: Mixed
  • Indication: HIV